Literature DB >> 35557583

Comparison of prognostic factors of esophageal cancer between a Chinese cohort and the Surveillance, Epidemiology, and End Results (SEER) database: a retrospective cohort study.

Bin Hu1, Yiyao Zhu1, Xiaobo Wu1.   

Abstract

Background: Esophageal cancer is a highly aggressive, early metastasis gastrointestinal malignancy, with geographic differences in prognosis. It is unknown whether there are differences in the survival in different regions among esophageal cancer patients who underwent the treatments. This study was to explore the influencing factors of esophageal cancer survival in patients from China and the Surveillance, Epidemiology, and End Results (SEER) database.
Methods: The retrospective cohort study were conducted with 605 Chinese esophageal cancer patients in the Wuxi People's Hospital and 2,351 patients from the SEER database. The demographic and clinical data were collected from the two cohort, respectively. The outcome was the death during the follow-up. The follow-up ended on November 30, 2021. The Cox proportional hazards model was used in the univariate and multivariate survival analyses, with hazard ratio (HR) and 95% confidence interval (CI).
Results: In group one, the following were identified as the prognostic factors: female gender (HR =0.568; 95% CI: 0.398-0.811), T3 and T4 stages (HR =3.312; 95% CI: 2.493-4.401), N2 and N3 stages (HR =3.562; 95% CI: 2.631-4.824), and other subtypes of cancer (HR =0.393; 95% CI: 0.223-0.693). The following prognostic were factors identified in group two: age ≥65 years (HR =1.16; 95% CI: 1.058-1.276), female gender (HR =0.843; 95% CI: 0.752-0.945), T3 and T4 stages (HR =1.523; 95% CI: 1.373-1.690), M1 stage (HR =2.554; 95% CI: 2.303-2.832), treatment with surgery and chemotherapy (HR =0.507; 95% CI: 0.457-0.562), and other subtypes of cancer (HR =1.432; 95% CI: 1.298-1.581). Conclusions: There may be some differences in prognostic factors between Chinese and American patients with esophageal cancer. It is indicated that different management strategies of esophageal cancer should be considered in different populations to improve the prognosis of patients. 2022 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  China; Esophageal cancer; Surveillance, Epidemiology, and End Results (SEER); comparison; prognostic factors

Year:  2022        PMID: 35557583      PMCID: PMC9086052          DOI: 10.21037/jgo-22-145

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  26 in total

1.  Esophagectomy with extended lymphadenectomy for submucosal esophageal cancer: long-term outcomes and prognostic factors.

Authors:  Toshiaki Tanaka; Satoru Matono; Takeshi Nagano; Kazuo Shirouzu; Hiromasa Fujita; Hideaki Yamana
Journal:  Ann Surg Oncol       Date:  2011-08-23       Impact factor: 5.344

2.  Comparison of clinicopathologic features and survival between eastern and western population with esophageal squamous cell carcinoma.

Authors:  Jie Zhang; Yizhou Jiang; Chunxiao Wu; Shuang Cai; Rui Wang; Ying Zhen; Sufeng Chen; Kuaile Zhao; Yangle Huang; James Luketich; Haiquan Chen
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

3.  Treatment and survival outcomes of small cell carcinoma of the esophagus: an analysis of the National Cancer Data Base.

Authors:  Andrew T Wong; Meng Shao; Justin Rineer; Virginia Osborn; David Schwartz; David Schreiber
Journal:  Dis Esophagus       Date:  2017-02-01       Impact factor: 3.429

4.  Tumor Size as a Critical Prognostic Factor in T1-2 Stage Esophageal Cancer.

Authors:  Zilong Wu; Bentong Yu
Journal:  Gastroenterol Res Pract       Date:  2020-08-17       Impact factor: 2.260

5.  Prognostic significance of lymph node metastases and ratio in esophageal cancer.

Authors:  Matthew Wilson; Ernest L Rosato; Karen A Chojnacki; Inna Chervoneva; John C Kairys; Herbert E Cohn; Francis E Rosato; Adam C Berger
Journal:  J Surg Res       Date:  2007-08-28       Impact factor: 2.192

6.  Primary small cell carcinoma of the esophagus: Comparison between a Chinese cohort and Surveillance, Epidemiology, and End Results (SEER) data.

Authors:  Qin Xiao; Haifan Xiao; Shuyu Ouyang; Jinming Tang; Baihua Zhang; Hui Wang
Journal:  Cancer Med       Date:  2019-02-10       Impact factor: 4.452

7.  Survival benefit of perioperative chemotherapy for T1-3N0M0 stage esophageal cancer: a SEER database analysis.

Authors:  Yue Shao; Dan Chen; Liu Ye; Xin-Mei Wang; Qing-Chen Wu; Cheng Zhang
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

8.  Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries.

Authors:  Hongmei Zeng; Rongshou Zheng; Siwei Zhang; Tingting Zuo; Changfa Xia; Xiaonong Zou; Wanqing Chen
Journal:  Thorac Cancer       Date:  2015-12-07       Impact factor: 3.500

9.  Adjuvant Therapeutic Modalities in Primary Small Cell Carcinoma of Esophagus Patients: A Retrospective Cohort Study of Multicenter Clinical Outcomes.

Authors:  Bingwen Zou; Tao Li; Qiang Zhou; Daiyuan Ma; Yongshun Chen; Meijuan Huang; Feng Peng; Yong Xu; Jiang Zhu; Zhenyu Ding; Lin Zhou; Jin Wang; Li Ren; Min Yu; Youling Gong; Yanying Li; Longqi Chen; You Lu
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

10.  Specific DNA methylation markers in the diagnosis and prognosis of esophageal cancer.

Authors:  DaPeng Li; Lei Zhang; YuPeng Liu; HongRu Sun; Justina Ucheojor Onwuka; ZhiGang Zhao; WenJing Tian; Jing Xu; YaShuang Zhao; HongYu Xu
Journal:  Aging (Albany NY)       Date:  2019-12-13       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.